Skip to main content
. Author manuscript; available in PMC: 2010 Sep 1.
Published in final edited form as: Spine (Phila Pa 1976). 2009 Sep 1;34(19):2096–2103. doi: 10.1097/BRS.0b013e3181b1fab2

Table 5.

Complications and Outcomes*

EACA
(n = 91)
Placebo
(n = 91)
P Value
Potential complications of transfusion - no. (%)
Wound infection 0 0 --
Nosocomial pneumonia 1 (1.1) 2 (2.2) 0.56
Central venous line infection 0 0 --
Urinary tract infection 1 (1.1) 1 (1.1) 1.00
Any infectious complication 2 (2.2) 3 (3.3) 0.65
Potential complications of EACA - no. (%)
Deep venous thrombosis 0 2 (2.2) 0.16
Cerebral infarction/ TIA 0 1 (1.1) 0.32
Myocardial infarction 0 0 --
Pulmonary embolism 1 (1.1) 3 (3.3) 0.31
Acute renal failure 1 (1.1) 1 (1.1) 1.00
Any thrombotic complication 2 (2.2) 6 (6.6) 0.15
Potential surgical complications - no. (%)
Reoperation due to bleeding 0 2 (2.2) 0.16
Outcomes - no. (%)
In-hospital mortality 0 1 (1.1) 0.32
ICU length of stay - days 1.8 ± 1.6 2.8 ± 4.6 0.04
Hospital length of stay - days 8.5 ± 3.9 9.5 ± 8.6 0.32
Total hospital charges - dollars 62,344 ± 27,497 68,670 ± 32,141 0.16
*

P values determined by Fisher’s exact test, two-sample t-test with unequal variances or Mann-Whitney rank-sum test as appropriate. Plus-minus values are mean ± SD. TIA is transient ischemic attack. ICU is intensive care unit. There were no differences in the incidence of clinically identified infections or thromboembolic complications. ICU LOS in the EACA group was significantly less, however, in-hospital LOS and charges were similar between the groups.